Streamlining Validation to Save Over $130K Annually and Accelerate Compliance | Global Gene Therapy CDMO Case Study
A global CDMO operating nine manufacturing facilities faced fragmented validation processes across locations and rising FTE hours spent on outdated workflows, made more urgent by a Microsoft Dynamics ERP implementation. It implemented Res_Q to standardize validation documentation, add unified dashboards for leadership visibility, and support acquisition-driven growth on a scalable platform. Results included a 53% reduction in effort per project, $130K in projected annual labor savings (2,070 hours annually, equivalent to 1 FTE), 20–40% faster test execution, approval cycles cut from weeks to days, and successful early FDA approvals for three critical SaaS systems.
Sware is a GxP validation platform whose entire commercial focus is life sciences — used specifically to validate AI/ML systems' explainable, traceable decisions for regulatory scrutiny.
This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.
Published by Sware on its own site — read the original case study on sware.com ↗
Related use cases
- 01Enabling a CDMO to Modernize Validation and Save 1.5 FTE Annually
- 02Helping a precision medicine company implement rapid, scalable GxP Validation | Biopharma Company Case Study
- 03Partnering for success in life sciences | Nuvolo Case Study
- 04Biotech company cuts validation time by 40% with Res_Q
- 05Pharma research company accelerates validation processes by 75% with Res_Q
- 06Molecular medicine company modernizes validation to reduce risk and cost